GLP-1 medications are famous for weight loss right now. But they were originally designed for something else: type 2 diabetes.
For people with diabetes, GLP-1s are one of the most effective treatments available. Here's what they do, how they work, and why your doctor might recommend one.
How GLP-1s Help with Diabetes
GLP-1 medications do three things that directly improve blood sugar:
1. They Help Your Body Release Insulin
When your blood sugar goes up after eating, GLP-1s tell your pancreas to release more insulin. Insulin is the hormone that moves sugar from your blood into your cells.
Important: GLP-1s only trigger insulin release when blood sugar is high. They don't push insulin when you don't need it. This means a much lower risk of dangerous low blood sugar compared to some other diabetes drugs.
2. They Stop Your Liver from Releasing Extra Sugar
Your liver releases sugar into your blood between meals. In type 2 diabetes, the liver releases too much. GLP-1s tell the liver to slow down.
3. They Slow Down Digestion
Food enters your bloodstream more slowly. This means blood sugar rises more gradually after meals instead of spiking.
Related products:
- Blood glucose monitor - track blood sugar at home
- Smart scale - monitor weight and body composition
What the Research Shows
The results are strong:
- A1C reduction: GLP-1s typically lower A1C by 1-2 percentage points. That's comparable to many other diabetes medications.
- Weight loss: Unlike many diabetes drugs that cause weight gain, GLP-1s cause weight loss. This is a big deal — excess weight makes diabetes harder to manage.
- Heart benefits: Some GLP-1s (semaglutide, liraglutide, dulaglutide) have been shown to reduce the risk of heart attack and stroke in people with type 2 diabetes.
- Kidney benefits: Recent studies show semaglutide may slow kidney disease progression in people with diabetes.
HbA1c Reduction by Drug: What the Trials Show
The numbers below are average HbA1c reductions from the pivotal trials — the change in percentage points from each trial's starting average. They come from different trials with different starting A1c levels, durations, and background medicines, so they are not a head-to-head ranking. The head-to-head comparisons are marked.
| Drug | Trial | Average HbA1c reduction | What to know |
|---|---|---|---|
| Tirzepatide (Mounjaro) | SURPASS-2, 40 weeks, 1,879 adults | −2.01 pp (5 mg), −2.24 pp (10 mg), −2.30 pp (15 mg) | Head-to-head vs semaglutide 1 mg (−1.86 pp); tirzepatide was superior at all three doses |
| Semaglutide injection (Ozempic) | SUSTAIN program, 30–56 weeks | −1.5 to −1.8 pp (0.5–1 mg) | SUSTAIN FORTE: −2.2 pp at the 2 mg weekly dose over 40 weeks |
| Oral semaglutide (Rybelsus) | PIONEER program | −1.0 to −1.4 pp | Lower and more variable than the injection, consistent with tablet absorption |
| Dulaglutide (Trulicity) | SUSTAIN-7, 40 weeks | −1.1 pp (0.75 mg), −1.4 pp (1.5 mg) | Head-to-head vs semaglutide 1 mg (−1.8 pp); semaglutide was superior at both dose tiers |
| Liraglutide (Victoza) | SUSTAIN-10, 30 weeks | −1.0 pp (1.2 mg daily) | Head-to-head vs semaglutide 1.0 mg (−1.7 pp) |
The pattern across the trials: the drugs with the largest average A1c reductions are also the ones with the largest average weight loss. That is expected — the same mechanism drives both. For an individual, the starting A1c, other medicines, and kidney function matter more than the table average.
Where GLP-1s Sit in the ADA Standards of Care
The American Diabetes Association's Standards of Care in Diabetes position GLP-1 receptor agonists as a first-line option — not a last resort — for adults with type 2 diabetes in three situations:
- With heart disease or high cardiovascular risk: a GLP-1 with proven cardiovascular benefit (semaglutide, dulaglutide, liraglutide) is recommended regardless of whether the A1c target is already met, because the heart benefit is separate from the blood-sugar benefit.
- With kidney disease: GLP-1s are recommended alongside SGLT2 inhibitors for people with type 2 diabetes and chronic kidney disease, with the choice driven by kidney function and other conditions.
- With overweight or obesity: weight management is part of diabetes care in the Standards, and GLP-1s are the drug class that addresses blood sugar and weight together.
In practice, that means a GLP-1 is often prescribed alongside metformin, or instead of adding a second drug that causes weight gain. It does not replace metformin for everyone, and it does not replace insulin when blood sugar is very high or when the pancreas no longer makes enough insulin.
This page is the site's diabetes hub. For the day-to-day side of living with diabetes on a GLP-1 — blood sugar monitoring, low blood sugar risk when combined with insulin or sulfonylureas, and CGM patterns after dose day — see our blood sugar guide. For blood pressure, which usually travels with diabetes, see GLP-1s and Blood Pressure.
Practical side-effect tips, one email a week
Nausea, constipation, fatigue and more: food-first fixes and questions worth asking your prescriber. Free.
Which GLP-1s Are Used for Diabetes
- Ozempic (semaglutide) — FDA-approved for type 2 diabetes
- Mounjaro (tirzepatide) — FDA-approved for type 2 diabetes
- Trulicity (dulaglutide) — FDA-approved for type 2 diabetes. See our Trulicity for weight loss guide for what the research shows.
- Victoza (liraglutide) — FDA-approved for type 2 diabetes
- Bydureon (exenatide) — FDA-approved for type 2 diabetes
- Adlyxin (lixisenatide) — FDA-approved for type 2 diabetes
The same active ingredients are often available under different brand names for weight loss (Wegovy = semaglutide, Zepbound = tirzepatide). The medication is the same — the approved use is different.
GLP-1s vs. Other Diabetes Medications
Compared to metformin:
- GLP-1s are more effective at lowering A1C
- GLP-1s cause weight loss (metformin is usually weight-neutral)
- Metformin is cheaper and has been used longer
- Many doctors prescribe both together
Compared to insulin:
- GLP-1s don't usually cause low blood sugar (insulin does)
- GLP-1s cause weight loss (insulin often causes weight gain)
- Insulin is more powerful for very high blood sugar
- GLP-1s are injections once weekly (insulin is often daily or multiple times per day)
Compared to SGLT2 inhibitors (Jardiance, Farxiga):
- Both lower A1C and help with weight
- SGLT2 inhibitors work through the kidneys (you pee out extra sugar)
- GLP-1s work through the gut and pancreas
- Some doctors prescribe both together for maximum benefit
What to Expect When You Start
First week: You may feel nauseous or have an upset stomach. This usually improves.
First month: Your blood sugar should start coming down. Your doctor may check your fasting glucose.
3 months: Your A1C should show improvement. This is when your doctor will check if the dose is right.
Long-term: Consistent A1C control, weight loss, and potential heart and kidney benefits.
Things to Watch For
- Low blood sugar: Uncommon on GLP-1s alone, but possible if you also take insulin or sulfonylureas. Your doctor may lower those doses when you start a GLP-1.
- Stomach side effects: Nausea, constipation, diarrhea — usually improve over time.
- Pancreatitis: Rare but serious. Seek care for severe, persistent abdominal pain.
The Bottom Line
GLP-1 medications are powerful tools for type 2 diabetes. They lower blood sugar, help you lose weight, and may protect your heart and kidneys.
Your action items:
- Talk to your doctor about whether a GLP-1 is right for you
- If you take insulin or sulfonylureas, ask about dose adjustments
- Monitor your blood sugar closely in the first few weeks
- Expect stomach side effects — they usually improve
- Don't stop other diabetes medications without talking to your doctor
GLP-1s aren't just weight loss drugs. They're diabetes drugs that happen to help with weight too. And for many people with type 2 diabetes, that combination is exactly what they need.
This article is for informational purposes only and does not replace medical advice. Always talk to your healthcare provider about diabetes management and medication changes.
Found this helpful? Share it with someone managing type 2 diabetes who might benefit from a GLP-1.



